ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Eloxx Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$12.50−0.53 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $84.86M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$12.50 (+∞%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Eloxx Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$6.44M
FY2025
EPS, diluted
-$0.49
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $84.86M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.83
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$6.00M
- EPS, diluted
- -$0.49
- Book value per share
- $6.84
- Diluted shares
- 7M
Fifteen years at a glance
Fiscal years 2010 to 2025, USD
Revenue
$0-100.0% YoY
Operating income
-$6.44M
Net income
-$6.00M
EPS, diluted
-$0.49
Free cash flow
–
Reported period